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Transcriptional R-loops represent a potential threat to genome integrity. Hatchi et al. show that BRCA1, in partnership with SETX, is engaged in a DNA repair mechanism that deals with Rloop-associated genomic instability at transcriptional termination pause sites.
INTRODUCTION
Germline mutations of the breast cancer susceptibility gene 1 (BRCA1) significantly increase the risk of developing breast and ovarian cancers (Tutt and Ashworth, 2002) . Since its discovery, researchers have intensively investigated the mechanisms by which full-length BRCA1 (p220) functions as a tumor suppressor.
BRCA1 is engaged in numerous direct and indirect physical interactions with specific partner proteins (Huen et al., 2010) . As part of several complexes, BRCA1 contributes to double-strand DNA break (DSB) repair by homologous recombination (HR), stalled fork repair, cell-cycle checkpoint activation, transcription regulation, heterochromatin maintenance, mitotic spindle formation, RNA splicing control, and estrogen metabolism (Gardini et al., 2014; Gorski et al., 2011; Mullan et al., 2006; Pathania et al., 2011; Savage et al., 2014a Savage et al., , 2014b Venkitaraman, 2014; Zhu et al., 2011) . Many of these BRCA1 properties and, in particular, those that protect genome integrity, probably contribute to its tumor suppressing function (Silver and Livingston, 2012; Tutt and Ashworth, 2002) . However, in the absence of a coherent underlying mechanism, there is still no definitive evidence of which specific BRCA1 functions are required for breast and ovarian cancer suppression (Huen et al., 2010; Venkitaraman, 2014) . Therefore, identifying new BRCA1 binding partners and their associated functions may yield valuable insights.
Our laboratory has identified senataxin (SETX) as a putative BRCA1 binding partner in a yeast two hybrid and several, independent TAP-MS-based genome-wide BRCA1/protein interaction screens (Hill et al., 2014; and D.M.L., unpublished data) . Disruption of the Setx gene in mice leads to a defect in spermatogenesis, caused by failure of meiotic recombination (Becherel et al., 2013) . Sen1, the SETX yeast homolog, was shown to contribute to the processing of various RNA species and to the distribution of RNA polymerase II (RNAPII) across the genome (Mischo et al., 2011; Steinmetz et al., 2006; Ursic et al., 1997) . This probably occurs via its direct interaction with RNAPII and certain RNA processing factors .
While transcription is an essential cellular process, it also represents a potential threat to genome integrity (Kim and Jinks-Robertson, 2012) . Several studies indicate that highly transcribed genes exhibit increased rates of mutation and illegitimate recombination (Gaillard et al., 2013) . Moreover, a large body of evidence indicates that mutations in certain factors involved at the interface of transcription and RNA processing are associated with genomic instability (Bhatia et al., 2014; Chan et al., 2014; Kleiman and Manley, 1999; Kleiman et al., 2005; Li and Manley, 2006; Stirling et al., 2012) . An emerging view is that these mutants contribute to the above-noted phenomena through a common mechanism, which induces the abnormal persistence of co-transcriptional R-loops (three-stranded structures, each consisting of an RNA:DNA hybrid plus the coding strand DNA). Although R-loops are a naturally occurring consequence of transcription and are essential for diverse cellular events , they can be potentially deleterious to some cellular functions and compromise genome integrity (Aguilera and García-Muse, 2012; Hamperl and Cimprich, 2014) . Indeed, unresolved Rloop structures can expose the displaced, coding ssDNA to nicking and/or other forms of damage (Daniel and Nussenzweig, 2013; Wimberly et al., 2013) , as well as impair transcription (Aguilera, 2002; Huertas and Aguilera, 2003) and DNA replication fork progression (Gan et al., 2011; Helmrich et al., 2011) .
Interestingly, SETX is involved in RNAPII transcription termination and resolves R-loops that form at G-rich transcription pause sites . It also associates with processing replication forks and facilitates their progression through RNAPII transcribed genes by displacing R-loops (Alzu et al., 2012) . In part through its genetic interaction with DNA repair genes involved in HR, senataxin also protects the genome from transcription-associated instability (Mischo et al., 2011; Ursic et al., 2004) . Similarly, SETX, by resolving R-loops at sites of transcription and replication collision, is engaged at the interface of replication stress, transcription, and DNA damage (Yü ce and West, 2013) .
Interestingly, BRCA1-containing complexes restrict DNA damage induced by aberrant transcription or RNA processing via proposed interactions with multiple transcription and RNA processing factors, including RNAPII (Anderson et al., 1998; Bennett et al., 2008; Kawai and Amano, 2012; Kleiman and Manley, 1999; Kleiman et al., 2005; Savage et al., 2014a; .
In view of these associations, we have asked whether BRCA1 plays a significant role in the repair of R-loop-associated DNA damage arising at termination sites. We find that BRCA1 and SETX form a physiological complex, recruited in a BRCA1-dependent manner to a subset of transcription termination pause sites of highly transcribed genes. There they act to suppress cotranscriptional R-loop-associated DNA damage. Unexpectedly, in breast tumor tissues carrying inherited BRCA1 mutations, insertion/deletion somatic mutations were found in the vicinity of BRCA1-bound gene termination sites where BRCA1 normally engages in the repair of R-loop-associated DNA damage.
RESULTS
Identification of BRCA1 as a Scaffolding Partner for SETX at the b-actin Transcription Termination Site To investigate whether BRCA1 is involved in R-loop-driven DNA damage responses, we first assessed the physiological relevance of a BRCA1 and SETX interaction, recently identified in our proteomic screens (Hill et al., 2014) and suggested by others (Becherel et al., 2013) . Endogenous BRCA1 and SETX co-immunoprecipitation (co-IP) was carried out in HeLa cell extracts, using two, different mono-specific antibodies (Abs) (Figures S1A and S1B). IP of each protein revealed significant co-IP of the other. Irrelevant IgG gave negative results. These results imply the existence of endogenous BRCA1/SETX-containing complexes in these cells ( Figure 1A ). Weak or undetectable co-IP followed RNAi-driven BRCA1 and SETX depletion, thereby validating Ab specificity ( Figure S1C ). Two-way BRCA1/SETX co-IP was also apparent in primary, diploid human BJ-hTERT fibroblast extracts ( Figure 1A , bottom), suggesting the existence of a physiological interaction between BRCA1 and SETX.
In an effort to map BRCA1 and SETX domains that participate in their interaction, we tested multiple, GST-tagged recombinant fragments that contain various BRCA1 and SETX sequences in glutathione S-transferase (GST) binding assays (Figure S1D ). The results showed that SETX interacts with F6C, which contains a BRCT (BRCA1 C-terminal) motif ( Figure 1B) . Intriguingly, F6, which also includes F6C, did not interact with SETX, although F6 was sufficiently folded to interact with another BRCT domain binding protein, BACH1 ( Figure S1E ) (Cantor et al., 2001) . Reciprocal SETX mapping revealed that fragment S8 interacted with BRCA1 (Figure 1C) . These results imply that specific structural units of both proteins participate in their interaction. A more extensive analysis will be required to obtain a full picture of this process.
In light of the existence of BRCA1/SETX binding, we tested for BRCA1 co-recruitment at transcription termination sites associated with R-loops by chromatin immunoprecipitation (ChIP) performed on the endogenous human b-actin gene ( Figure 1D ) . Cross-linked HeLa cell chromatin was harvested before and after siRNA depletion of either BRCA1 or SETX. Depletion efficiency was verified at the protein level ( Figure 1E ).
Specifically, we found that in mock siRNA-transfected cells BRCA1 binding was significantly enriched (3-to 6-fold) at the transcription termination site (5 0 pause and pause site probes) when compared to the signals obtained following BRCA1 depletion ( Figure 1F ). Notably, while BRCA1 depletion suppressed these binding signals, SETX depletion did not. We also confirmed the existence of SETX accumulation at the b-actin transcription termination pause site ( Figure 1G ). BRCA1 depletion impaired SETX binding to these sites, implying that its recruitment is BRCA1 dependent at this locus. Similar results were obtained when BRCA1 and SETX hairpins were substituted for cognate siRNA species (Figures S2A and S2B) . These findings demonstrate a physiological BRCA1/ SETX interaction at the b-actin transcription termination site and suggest that BRCA1 acts as an anchor for SETX therein.
R-Loop Formation at the b-actin Gene Transcription
Termination Site Triggers BRCA1/SETX Complex Recruitment To search for a connection between the formation of R-loops and the recruitment of BRCA1/SETX at the b-actin termination site, we first asked whether RNA:DNA hybrids forming within this gene are affected by BRCA1 and SETX depletion. We measured R-loop formation over the b-actin gene, employing DNA:RNA hybrid immunoprecipitation (DIP) of uncross-linked DNA using a monoclonal Ab specific for RNA:DNA hybrids (S9.6) . As shown in Figure 2A , a modest, but reproducible, increase in R-loop abundance was detected within the b-actin gene pause site, following BRCA1 or SETX depletion. While this result suggests that BRCA1 and SETX affect R-loop formation, it is important to note that BRCA1 depletion also elicited a phenotype suggestive of a transcription termination defect that was previously reported upon SETX depletion. It was manifest by RNAPII accumulation at the pause site (Figure S2C ). The recruitment of other RNA:DNA helicases in the absence of SETX to resolve R-loops over these regions, as well as potential differences in transcription levels after BRCA1 and SETX depletion, might explain the lack of a more substantial increase in R-loops levels.
We then tested BRCA1 and SETX chromatin occupancy over the b-actin gene following R-loop suppression. ChIP experiments were performed in HeLa cells before and after overexpression of GFP-tagged RNaseH1 ( Figure S3A ), which significantly reduced R-loop formation over the b-actin gene . In RNaseH1-overexpressing cells, we observed a significant suppression of BRCA1 and SETX binding at the transcription termination site, as compared with control cells ( Figure 2B) . Moreover, as shown in Figure 2C , RNaseH1 overexpression led to a reduction in the co-IP signal, implying that BRCA1/SETX complex formation at these genomic loci is mediated by R-loops. Thus, our results suggest that BRCA1/SETX complexes bind at termination region (TR) sites in response to local R-loop formation and that they also suppress R-loop abundance, in part, by participating in the regulation of transcription and of transcription termination.
BRCA1/SETX Complexes Protect DNA at R-Loop-Associated Termination Pause Sites from the Development of ssDNA Breaks Since R-loop accumulation can increase the risk of genomic instability by promoting DNA damage (Hamperl and Cimprich, 2014; , we tested whether BRCA1 and/or SETX depletion triggers the generation of DNA damage in the vicinity of persistent R-loops. Specifically, gH2AX ChIP assays were performed over the b-actin gene. After depletion of either BRCA1 or SETX, we observed significantly increased signals of gH2AX largely restricted to the termination region ( Figure 3A ). This implied that loss of BRCA1/SETX complexes over the R-loop-associated pause site contributed to the accumulation of local damage.
Since several studies suggest that the ssDNA of an R-loop is prone to transcription-associated mutations or DNA breaks (Aguilera and García-Muse, 2012; Wimberly et al., 2013) , we adapted a ligation-mediated quantitative PCR (LM-qPCR) approach to test whether ssDNA breaks had occurred on the non-template strand following BRCA1 or SETX depletion (Figure 3B) . Briefly, we ligated an adaptor to putative ssDNA ends after performing a primer extension reaction over the far 3 0 end of the b-actin gene. The goal was to amplify any post-ligation DNA fragments that harbor both the adaptor sequence and a segment of the 3 0 end of the b-actin gene. In the absence of BRCA1 or SETX, significant signals were observed when using 5 0 pause and pause site primers, thereby reflecting the existence of one or more ssDNA breaks located near the termination region ( Figures 3C and S3B) . The 3 0 Rloop-free C region ( Figure 2A ) was used as a negative control to validate the specificity of the above-noted results. We also tested the anti-sense strand and failed to observe LM-qPCR signals above background following BRCA1 or SETX depletion (Figure S3C) . This suggested that the observed breaks affected only the non-template strand.
We then asked whether RNaseH1 overexpression suppressed the appearance of ssDNA breaks in the b-actin gene in BRCA1-or SETX-depleted cells. The background signals in control region C remained barely detectable, while RNaseH1-expressing BRCA1-or SETX-depleted cells revealed a significant signal decrease within the 5 0 pause and pause regions (Figures 3C and S3B) . Taken together, these data argue that, in the b-actin gene, BRCA1 and SETX are involved in the prevention/repair of ssDNA breaks arising within the coding strand R-loop near their 3 0 end binding site(s).
BRCA1/SETX Complexes Form at Several R-Loop-Associated Genomic Loci and Protect Cells from the Development of ssDNA Breaks To search for a global effect of BRCA1/SETX function, we first searched for evidence within two gene sets. On one hand, we analyzed two genes (ENSA, Gemin7) in which transcription termination is also dependent on R-loops . In both genes, BRCA1 and SETX binding was enriched at the relevant transcription termination regions as compared to an irrelevant intronic segment (Figures 4A, 4B, S4A, and S4B) . Although the BRCA1 antibody used in ChIP experiments displayed some background signal, its specificity was confirmed by its sensitivity to BRCA1 depletion. In parallel, we studied the Akirin1 and cyclinB1 genes in which transcription termination is regulated by an R-loop-free co-transcriptional cleavage (CoTC) mechanism White et al., 2013) . BRCA1 and SETX ChIP analysis revealed no specific signals in either intronic region or the CoTC regions of Akirin1 and cyclinB1, reinforcing the hypothesis that BRCA1/SETX recruitment requires R-loop formation (Figures 4A, 4B, S4A, and S4B). We also examined the DNA damage signaling response in these two categories of genes by searching for gH2AX signals over the termination regions using ChIP qPCR. Similar to b-actin, increased gH2AX signals were clearly visible over the pause element of both ENSA and Gemin7 following BRCA1 or SETX depletion, but not over the control intronic region (Figures 4C and S4C) . By contrast, no gH2AX enrichment was detected at ''R-loop-free'' CoTC termination regions within Akirin1 or cyclinB1. These results are consistent with our b-actin ChIP data ( Figure 3A ) and with the presence of local gH2AX signals in the absence of BRCA1/SETX complexes over ENSA and Gemin7. Thus, they can be viewed as a reflection of local R-loop-associated DNA damage. These findings imply that BRCA1/SETX complexes participate in the repair or prevention of this form of damage in these two genes bearing R-loop-associated transcription termination regions.
We then asked whether BRCA1/SETX function at R-loop-forming termination sites is a genome-wide phenomenon. First, comet assays were performed to search for widespread DNA breaks as a consequence of BRCA1 or SETX depletion. As predicted, under alkaline conditions, which detect both ssDNA breaks and DSBs, we observed a significant increase in comet tail lengths in both BRCA1-and SETX-depleted cells. Moreover, RNaseH1 overexpression in both settings decreased the abundance of cells with comets as well as their length ( Figures 4D and 4E ). Similar results were observed when the cells were treated with a low dose of a-amanitin that acts to inhibit RNAPII elongation. These results confirm that R-loop structures, as by-products of transcription, create numerous fragile genomic sequences prone to BRCA1/ SETX depletion-associated damage. Although we also observed an increase in comet tail lengths in BRCA1-and SETX-depleted cells assayed in neutral buffer conditions (probably reflecting DSB), these DNA damage phenotypes did not revert after overexpression of RNaseH1 or exposure to a-amanitin (Figure S4D ). Thus, R-loop-dependent DNA damage following BRCA1/SETX depletion is mainly composed of ssDNA breaks.
BRCA1 Is Globally Associated with Transcription Termination Sites of Highly Transcribed Genes
In light of the possibility that R-loop-associated termination regions are characteristics of larger numbers of genes, we performed a meta-analysis from several deep-sequencing datasets to search for genomic co-localization of BRCA1 peaks at transcription termination regions. We used the ENCODE BRCA1 ChIP-seq dataset to identify candidate genes regulated by this mechanism . For each gene, a candidate transcription TR was defined as a 4 kb segment downstream of the transcription termination site (TTS) ( Figure 5A ).
Initially, 764 distinct BRCA1 peaks significantly overlapping a genomic TR were identified. Since BRCA1 is also associated with a subset of promoters (K.M.M. et al., unpublished data) (Gardini et al., 2014) , we further filtered these data to exclude any peaks overlapping promoter regions and their associated See also Figure S5 and Table S1 .
transcripts. In this filtered gene set, 196 BRCA1 peaks, each associated with a TR, corresponded to 184 genes that are referred to here as BRCA1 TR genes ( Figure 5B and Table S1 ).
Since the DNA damage that developed over R-loop-associated TRs upon BRCA1/SETX depletion is proposed to be Rloop and, therefore, transcription dependent, we analyzed the expression levels of these BRCA1 TR genes. RNA-seq data were used to analyze HeLa cell transcriptomes available from ENCODE. The expression profiles of genes whose filtered TRs did or did not overlap BRCA1 ChIP-seq peaks were compared. The data showed that BRCA1 TR genes clearly displayed higher mRNA levels (p = 1.1E-7), when compared to genes whose termination sites are not associated with a BRCA1 binding site (Figures 5C and S5 and Table S1 ). These results indicate that BRCA1 TR genes are more highly expressed than those lacking BRCA1 TR binding peaks.
To explore further whether BRCA1 binding at TR is associated with transcription termination, we searched for evidence of the co-localization at termination sites of BRCA1 peaks and RNAPII paused at the 3 0 end of the relevant genes (RNAPII S2P) (Davidson et al., 2014) . Here we used ENCODE RNAPII CTD Ser2-P ChIP-seq data . This analysis showed that more than 70% of BRCA1 peaks within TRs overlap paused RNAPII ( Figure 5D and Table S1 ), suggesting that BRCA1 is actively engaged in transcription-associated events at termination sites. To investigate whether BRCA1 TR are associated with R-loops, we compared them with the RNA:DNA IP database (DRIP-seq) generated with cells before and after RNaseH1 treatment (DRIP+RH) . We found that BRCA1 TR peaks show a significant enrichment of DRIP signal as compared to DRIP+RH ( Figure 5E ), implying the existence of R-loop formation at the BRCA1-associated TR loci.
These results suggest that in mammalian cells BRCA1 binds to TR (associated with paused RNAPII) in a substantial subset of highly transcribed genes, whose pause sites reflect a strong tendency to form R-loops. Taken together, our findings indicate that BRCA1 and SETX participate in the prevention/repair of ssDNA damage occurring at specific regions (TRs) in response to the transcription-associated formation of R-loops in physiological conditions. Conceivably, these genes require BRCA1/SETXdependent DNA damage surveillance to ensure regulation of transcription (Huppert et al., 2008; ).
BRCA1 Mutant Breast Cancers Reveal Genomic Alterations at BRCA1-Associated Termination Sites
We next asked whether a defect in the newly detected BRCA1/ SETX function could participate in the pathogenesis of BRCA1-deficient breast cancer tumors. Recent large-scale DNA sequencing screens performed in various human cancers have shed light on the nature and location of associated somatic mutations (Alexandrov et al., 2013; Pleasance et al., 2010) . We performed a mutation analysis in the 184 BRCA1 TR genes, using the complete catalog of somatic mutations obtained from the whole-genome sequencing of 21 breast cancers, a subset of which (n = 5) were BRCA1 mutant . This catalog includes single base mutations (SBMs), insertions and deletions (indels), and chromosomal rearrangements. For each patient, the genome of healthy/normal mammary tissue was also sequenced, and any mutations therein were deleted from the patient mutation analysis. Since R-loops can be long, we first included promoter regions in this search. More specifically, we first defined for each BRCA1 TR gene a whole gene region of special interest from TSS À 1,250 bp to TTS + 5 kb and searched for BRCA1-specific mutations.
We divided the 21 patient datasets into 3 breast cancer types: 12 sporadic (i.e., tumors WT/WT for both BRCA1 and BRCA2), 5 BRCA1, and 4 BRCA2 mutant tumors. Figure 6A compares each of the mutant groups to WT, in search of a quantitative measure of any difference in mutation rate (i.e., effect size) between any 2 groups. The effect size was computed as a standardized difference in mutation counts when all selected genes are considered together. It was obtained separately for each type of mutation analyzed. The results clearly indicate that, within the BRCA1 TR gene regions of interest, there was significant enrichment for indels only in the mutant BRCA1 tumors (z = 2.875, p = 0.009), despite the fact that more indels were detected throughout the entire genomes of BRCA2 than BRCA1 breast cancers . By contrast, these genomic loci were enriched for SBM in the BRCA2 tumors (z = 2.144, p = 0.021). Of note, no significant enrichment for rearrangements was observed. These results indicate that, within BRCA1 TR genes, distinct mutational patterns exist that separate BRCA1 and BRCA2 tumors. This suggests that any biochemical defects that the absence of these proteins elicits may, at least in part, be different.
In parallel, we also performed a global mutation analysis among the ''R-loop free'' CoTC-regulated genes (''negative'' genes) where BRCA1 is not recruited ( Figure 4A ). We failed to detect any significant change in the species of mutations detected in either BRCA1 or BRCA2 null tumors ( Figure S6 ).
To further investigate the mutational profile at the 3 0 ends of the BRCA1 TR genes, we focused on a narrower region defined as: TTS ± 4 kb. Strikingly, the only significant enrichment observed was for indels in BRCA1 mutant tumors (z = 3.464, p = 0.002) ( Figure 6B ). Precise mapping of the indels in the BRCA1 TR genes in the BRCA1 null tumors indicated that 3 out of 6 were located $300-400 bp from the BRCA1 TR peak; 2 were located further away (last intron and $1.8 kb downstream of the BRCA1 peak); and another was close to the promoter region ( Figures 6C-6E and Table S2 ). The absence of SBM enrichment in the 3 0 end regions of the TR genes in BRCA2 mutant carriers suggests that most of it accumulates at 5 0 ends and within the gene body. Of note, none of the few mutations detected in the CoTC genes was located in 3 0 end regions. Overall, these results show that BRCA1-deficient tumors are significantly enriched for indels in BRCA1 TR genes compared to BRCA2 and sporadic breast cancers. A significant fraction of the BRCA1 tumor-associated indels lie in the vicinity of BRCA1 binding TR loci, supporting the view that BRCA1 plays a critical role in preventing/repairing R-loop-mediated damage in the vicinity of R-loop-associated TR.
DISCUSSION
In this study, a combination of biochemical, molecular, and genetic data provides evidence that a newly identified BRCA1/SETX complex is required to restrain the development of R-loop-mediated DNA damage at specific genomic regions. In particular, we have delineated a sequence of events that is predicted to occur over a substantial subset of R-loop-associated transcriptional pause sites and, when impaired, results in the BRCA1 TRassociated indel mutations observed in BRCA1 À/À breast cancer genomes. Under physiological conditions, R-loops play a role in transcription termination at G-rich pause sites, like those in b-actin, Gemin7, and ENSA . They are also present at promoter regions where there is a region of GC-skew that ensures the protection of vicinal CpG island sequences against DNA methylation . Though these structures represent R-loops associated with distinct biological functions, they are, nonetheless, still predicted to induce DNA damage (for review see .
How BRCA1 recognizes R-loop structures remains to be determined. Current knowledge focuses mainly upon the factors that regulate their formation (Chan et al., 2014; Hamperl and Cimprich, 2014; . However, little is known about potential direct interaction between specific proteins and R-loops. Several possibilities exist. For example, there could be direct recognition of an RNA:DNA hybrid, e.g., as occurs with the hybrid-binding domain (HBD) of RNaseH1 (Cerritelli and Crouch, 2009) , and/or of the non-template ssDNA. For BRCA1, it is also possible that the branched structure of an R-loop resembles the DNA flaps, branched DNA, and/or four-way junctions for which BRCA1 exhibits an intrinsic affinity (Paull et al., 2001) . Alternatively, BRCA1 recruitment to R-loops could be mediated by other protein complexes that normally interact with these special DNA structures. These could be components of the RNAPII holoenzyme, splicing machinery, and/or specific chromatin remodeling complexes that are associated with R-loops (Bochar et al., 2000; Boulé and Zakian, 2007; Savage et al., 2014a; Yarden and Brody, 1999) .
Results presented here show that a deficiency in BRCA1/ SETX function results in unrepaired ssDNA breaks on the nontemplate strand at certain R-loop-associated TRs. gH2AX Figure S6 and Table S2. accumulation was observed by ChIP, although the extent of its genomic presence appears to be more restricted than observed at sites of DSB (Paull et al., 2000) . It is tempting to speculate that the restricted presence of gH2AX signals is a reflection of the presence of ssDNA breaks as the source of DNA damage and/ or that gH2AX spreading is antagonized by high levels of transcription (Iacovoni et al., 2010) .
The above considerations aside, how DNA damage occurs at such sites remains unknown. Multiple molecular mechanisms may foster or contribute to the DNA damage associated with R-loops. Superhelical stress and G4 and/or flap endonucleases could generate local ssDNA breaks, some of which could devolve into DSB (Hamperl and Cimprich, 2014) . In addition, genomewide sequencing of human cancers suggests that non-random, clustered mutations may be concentrated in long ssDNA regions, some of which might form R-loop structures . Indeed, during transcription, possibly due to the relative chemical susceptibility to damage of ssDNA, there is an increase in the mutation rate associated with the activity of editing enzymes like activation-induced cytosine deaminase (AID) or apolipoprotein B mRNA-editing catalytic polypeptide proteins (APOBEC) (Alexandrov et al., 2013; Beale et al., 2004; Chan et al., 2012) . Recently, the latter have been suggested to play a role in the mutational processes that affect breast cancer genomes (Burns et al., 2013; .
Taken together, our findings show that BRCA1 contributes to the control and/or repair of R-loop-mediated DNA damage at specific sites, which is, potentially, a significant contributor to the maintenance of genomic stability. Similarly, the implications of a proposed role for BRCA2 in transcription-associated recombination (TAR) and in the processing of R-loops in partnership with RNA processing factors suggest that these structures are a source of cancer-related instability (Bhatia et al., 2014; Gallardo et al., 2003; Huertas and Aguilera, 2003; Savolainen and Helleday, 2009) .
BRCA1-and BRCA2-mutant cancers exhibit differences in histopathology, gene expression profiles, and clinical course, even though they share similarities in their marked levels of genomic instability . By contrast, our observations imply that, at certain transcription termination regions, the mutational signatures of BRCA1 and BRCA2 null tumors are different. Conceivably, these differences arise from the possibility that BRCA1 and BRCA2 respond to/interact with R-loops differently and even in different contexts. Additional whole-genome sequencing from greater numbers of BRCA mutant cancers would be required to address these possibilities in the future. Further studies will also be needed to determine whether such BRCA1/BRCA2 mutational differences contribute directly or indirectly to the biological differences between BRCA1 and BRCA2 breast cancers.
EXPERIMENTAL PROCEDURES
For detailed experimental procedures, see Supplemental Experimental Procedures.
Co-Immunoprecipitation Analysis
Whole-cell extracts (WCE) were prepared as previously described (Tardat et al., 2010) , except that the lysis mixture was sonicated with a Sonic Dismem- 
Mutational Analyses of Breast Cancers
Detailed description of the computational and statistical analyses is available in Supplemental Experimental Procedures. The integrative Genomics Viewer (IGV) genome browser was used to visualize the indels and the BRCA1 and RNAPIISer2P ChIP-seq profiles across the termination regions of the BRCA1 TR genes (Thorvaldsdó ttir et al., 2013). These results confirm the specificity of the antibodies targeting BRCA1 and SETX.
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Input= 10% of protein used for co-IP. IgG, negative control.
(D) Schematic representation of the BRCA1 and SETX fragments produced in E.coli as
GST fusion proteins and respectively tested for binding to SETX and BRCA1 by GST binding assays ( Figure 1B ).
For BRCA1, the RING domain is shown by the orange N-terminal box; exon 11 is indicated in black; and the 2 BRCT motifs, located near the C-terminus are in dark red.
The numbers represent BRCA1 amino acid residues. For SETX, the helicase domain is shown is green. between the different tumor subgroups: BRCA1 mutant or BRCA2 mutant vs WT (non BRCA1/BRCA2 mutated) when testing the region ±4kb from a TTS. Tables   Table S1: List of BRCA1 peaks at GST binding assays. GST fragments (F1-F6 for BRCA1 and S1-S9 for SETX) have been described ). C-terminal fragments of BRCA1 (F6N and F6C) were PCR amplified and cloned into the GST bacterial expression vector, pET42a. GST fusion proteins were generated in BL21 (DE3) Na-deoxycholate and 250mM LiCl; 2X: 50mM HEPES pH 7.6, 1mM EDTA, 1% (v/v) NP-40, 0.7% Na-deoxycholate and 500mM LiCl and 3X with TE (10mM Tris.HCl pH7.5, 1mM EDTA). DNA was eluted from the magnetic beads with 0.1 M sodium carbonate and 1% (w/v) SDS. Samples were then brought to 300 mM NaCl and RNAse A (10 μg/ mL) and incubated at 65°C overnight to reverse crosslinks. DNA was purified with a PCR purification kit (Qiagen) according to the manufacturer's instructions. ChIP samples were quantified by quantitative real-time PCR using SYBR green mix (iTaq Universal, Biorad) and the primers of interest (see Table 1 for primers sequences). We analyzed the data using ABI PRISM 7900 Sequence Detection system software (Applied Biosystems). The results were calculated as %Input, representing the proportion of 100%
Supplemental
Input (total amount of chromatin used for each IP) or as fold enrichment over a given region.
Comet Assay. Alkaline and neutral comet assays were performed on HeLa cells using a Single Cell Gel Electrophoresis Assay Kit (Trevigen) according to the manufacturer's instructions. 1500 cells were spotted onto each sample area. The CellProfiler software (Carpenter et al., 2006) was used for analysis and quantification of the results.
LM-PCR and quantification of ssDNA breaks. HeLa cells were harvested 72h after siRNA-mediated depletion of BRCA1 or SETX, and genomic DNA (gDNA) was routinely purified using a DNeasy® kit (Qiagen). The LM-1 and LM-2 oligonucleotides were annealed as described (Schlissel et al., 1993) , and 300 pmoles of these adapters were phosphorylated with T4 Polynucleotide Kinase (New England Biolabs) and purified as described (Sambrook and Russell, 2006) . Antisense, gene-specific primers (GSPs) for the β-actin gene were used to detect ssDNA breaks on the sense strand of the gDNA. The assay was performed using 1 µg of gDNA per sample. DNA was denatured and first annealed with biotinylated-GSP1 primers. Primer extension from the 3'-end of the β-actin gene was accomplished with Deep Vent® DNA polymerase (New England Biolabs). Then, the ds blunt end DNA was ligated to the phosphorylated asymmetric/5'-overhanged double-stranded adaptor for 2 hrs at 22°C using 2.5 U of T4 DNA ligase (New England Biolabs) and a final adaptor concentration of 1nM. Dynal M280 streptavidin-coated magnetic beads (Invitrogen) were used to capture the ligated and extended β-actin DNA fragments, according to manufacturer's instructions. The beads were resuspended in 0.1X TE, and the equivalent of 50-100 ng of purified and ligated product were used as a template for a first round PCR reaction, using a nested gene specific primer (GSP2) and a linker primer. Samples were amplified for 12 cycles in a 3 step-protocol with Phusion High-Fidelity DNA polymerase in GC buffer (Thermo Scientific). PCR products were diluted (1/50) and processed by qPCR to amplify specific regions of interest along the β-actin gene, the 5'pause region and the pause region, itself, using the same primers that were used for ChIP experiments. We also included a negative control region, which was interrogated with primer C. It is located further downstream and outside of the primer-extended β-actin gene. As for ChIP experiments, the quantification of PCR products was analyzed with SYBR green (iTaq Universal, Biorad) using ABI PRISM 7900 Sequence Detection system software (Applied Biosystems). See Table 1 for primers sequences.
Genomic Analyses. Protein-coding transcripts were identified from an hg19 build based on GENCODE v10 annotations Harrow et al., 2012) . Putative transcription termination regions (TR) were defined as a 4 kb window downstream from the transcription termination site (TTS, end of the 3' UTR). When there were multiple transcripts sharing the same gene ID, the most downstream TTS was used. Termination regions were filtered out when they overlapped promoter regions.
Using the same protein-coding transcripts as above, we defined promoter regions as being located within a sequence 1250 bp upstream and 250 bp downstream of the transcription start site (TSS=beginning of the 5' UTR). When there were multiple transcripts sharing the same gene ID, the most upstream TSS was used. To define BRCA1 peaks, we used the officially processed, HeLa-S3 BRCA1 peaks as called by ENCODE Quinlan and Hall, 2010) We defined a BRCA1 peak/TR overlap as that of a termination region overlapping a BRCA1 peak, with the use of Bedtools Djebali et al., 2012; Quinlan and Hall, 2010) . We calculated the number of instances observed between any two groups, as well as the expected instances of overlap based on the hypothetical uniform distribution of the terminations regions (TR) and BRCA1 peaks. Specifically, let n 1 and n 2 be the respective number of regions of TR and BRCA1 peaks, while l 1 and l 2 is the respective total length of regions corresponding to TR and BRCA1 peaks. Furthermore, let x be the total size of the genome. Then, the expected instances of overlaps would be approximately E[Overlaps] = (n 1 *l 2 +n 2 *l 1 )/x, assuming uniform distributions of TR and BRCA1 peaks over the entire genome. When using all end sites (TR) and BRCA1 peaks, our search space was the size of the genome, while the use of filtered end sites and BRCA1 peaks allowed for the reduced search space of the size of the genome without promoters.
Using the expected and observed number of overlaps, we identified statistically significant enrichments for BRCA1 peaks at putative pause sites. To test the significance of the results, we used the upper tail of the cumulative Poisson distribution, with the expected number of overlaps as the mean.
For gene expression data, RNA-Seq quantifications were downloaded from the ENCODE RNA-Seq dashboard Djebali et al., 2012) . The RPKM scores were exported from the CSHL HeLa-S3, Long PolyA+, whole-cell extract RNASeq data with GENCODE v10 annotations. The quantifications were generated using the With the gene expression data, we were able to compare the expression of genes whose filtered end sites did or did not overlap the filtered BRCA1 peaks. We transformed the RPKM scores to log(RPKM+1), and generated a geometric box plot ( Figure 5C ) and a cumulative distribution plot ( Figure S4 ) using ggplot2 (Harrow et al., 2012; Wickham, 2009 ). Any gene whose putative pause site was filtered out in the previous steps was not included. The statistical significance of the variation between the two groups was tested using the non-parametric two-sided Mann-Whitney test.
To evaluate the overlap between BRCA1 peaks at end sites and RNAPIISer2P peaks, we used the RNAPIISer2P ChIP-seq data available from ENCODE at:
http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeSydhTfbs/wgEn codeSydhTfbsHelas3Pol2s2IggrabPk.narrowPeak.gz. To compute the p-value of BRCA1
TR and RNAPIISer2P peak overlap enrichment, we generated 10E7 random datasets having peak lengths and chromosomal distributions matching the experimental dataset.
None of them had the same or a larger number of overlaps than the original file, hence p<1.0E-7. For the meta-analysis of co-incidence between BRCA1 peaks at ends sites and R-loops, we used the DRIP-seq data . The statistical significance of the variation between the DRIP and DRIP+RH samples was tested using the nonparametric two-sided paired Wilxocon test, as the data did not conform to normal distribution.
Functional enrichment analyses. Gene IDs of BRCA1 TR genes corresponding to genes with at least one BRCA1 binding site in the termination region were uploaded into Ingenuity Pathway Analysis (IPA) to search for biological and molecular functions as well as disease associations that were significantly enriched in the data set. Each p-value was determined by the Fisher's exact test and corresponds to the probability that, in a given category, we could reach the observed enrichment, or a larger one, by chance alone. Select enrichments for the BRCA1 TR gene set are shown in Figure 5F , and the full list is accessible in Table S2 .
Mutational analyses of breast cancers. The BRCA1 TR genes as well as the CoTC "negative" genes were annotated in the hg19 build based on ENSEMBL format version 74 and scanned for each type of mutation. For each type of mutation, we computed a standardized mutation score (z-score) as follows. For each gene, we compared the observed number of mutations in BRCA1 or BRCA2 breast tumors to the number of mutations we would expect under the null hypothesis that the mutation rate in BRCA1 or BRCA2 breast tumor subgroup is equal to the mutation rate in the sporadic tumors (WT).
Then, for each subgroup of tumors, we computed the sum of the differences between observed and expected mutations across all genes; finally we standardized this sum as: zscore = (Total Observed -Total Expected) / Standard Deviation of Total Observed. This analysis produces a global standardized mutation score, where positive (or negative)
values indicated a higher (or lower) number of mutations than expected under the null hypothesis. Since mutational events are rare, we computed the p-values by Monte-Carlo simulation. First, we drew 10,000 global standardized mutation scores from the exact null distribution. Under the null hypothesis, the mutation score is equal to a sum of transformed hypergeometric random variables, one for each gene. Second, we computed the p-value as the proportion of simulated mutation scores, which are greater than, or equal to, the observed mutation score. 
